Spyre Therapeutics Q3 net loss widens more than expected on higher trial costs

What happened

Spyre Therapeutics said its third-quarter net loss widened more than expected, while its operating loss also missed estimates as research, development and trial costs rose. The company reported ending the quarter with $1.5 bln in cash after a public offering.

Confirmed

Global impact / market context

Rising research and trial costs directly increase cash outflows before drug studies produce revenue, so extended trials could use more of Spyre’s available funds. Its stated cash runway into the second half of 2029 offers time to pursue studies, but results and spending remain important to funding needs.

Analyst inference

The report pairs missed quarterly loss estimates with plans to advance an anti-TL1A treatment into pivotal hidradenitis suppurativa studies in 2027 and expected SKYLINE Part B results in Q3 2027. These milestones connect near-term spending to future clinical evidence, without confirming study outcomes.

Analyst inference

What to watch

1. Track research and clinical trial costs in upcoming results: continued increases could widen operating losses and consume cash faster than the company’s stated runway suggests. Analyst inference
2. Watch for the planned 2027 move of anti-TL1A monotherapy into pivotal HS studies; the company has announced this plan, but study progress is not yet reported. Proposed
3. Look for the expected SKYLINE Part B topline induction results in Q3 2027, which could provide clinical evidence relevant to the company’s development plans. Proposed

Evidence

• Original source link unavailable